CA2666709A1 - Method for treating age-related macular degeneration - Google Patents

Method for treating age-related macular degeneration Download PDF

Info

Publication number
CA2666709A1
CA2666709A1 CA002666709A CA2666709A CA2666709A1 CA 2666709 A1 CA2666709 A1 CA 2666709A1 CA 002666709 A CA002666709 A CA 002666709A CA 2666709 A CA2666709 A CA 2666709A CA 2666709 A1 CA2666709 A1 CA 2666709A1
Authority
CA
Canada
Prior art keywords
antibody
vegf
antibodies
region
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666709A
Other languages
English (en)
French (fr)
Inventor
Naveed Shams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666709A1 publication Critical patent/CA2666709A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002666709A 2006-11-10 2007-11-09 Method for treating age-related macular degeneration Abandoned CA2666709A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
US60/865,380 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (1)

Publication Number Publication Date
CA2666709A1 true CA2666709A1 (en) 2008-05-29

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666709A Abandoned CA2666709A1 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Country Status (6)

Country Link
US (2) US20100111963A1 (OSRAM)
EP (1) EP2089059A2 (OSRAM)
JP (1) JP2010509369A (OSRAM)
AU (1) AU2007323925A1 (OSRAM)
CA (1) CA2666709A1 (OSRAM)
WO (1) WO2008063932A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299701B2 (en) * 2004-10-21 2011-11-17 Genentech, Inc. Method for treating intraocular neovascular diseases
KR101737466B1 (ko) 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
SG10201510586PA (en) * 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
CN102711756A (zh) * 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2814439A1 (en) * 2010-10-27 2012-05-03 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JPWO2012105610A1 (ja) * 2011-02-02 2014-07-03 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US10548841B2 (en) * 2012-08-21 2020-02-04 Opko Pharmaceuticals, Llc Liposome formulations
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
RU2016114724A (ru) * 2013-10-08 2017-11-13 Ф. Хоффманн-Ля Рош Аг Применение n-(4-трет-бутилбензил)-3-хлор-n-[2-(4-хлор-3-этилфенил)-этил]-2-фтор-5-трифторметилбензамида для лечения глазных заболеваний
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3362095B1 (en) * 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
HRP20231379T1 (hr) 2015-12-03 2024-02-16 Regeneron Pharmaceuticals, Inc. Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3515536A1 (en) * 2016-09-19 2019-07-31 Lupin Limited In-line filter for protein/peptide drug administration
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JPWO2019151470A1 (ja) 2018-02-02 2021-02-25 国立大学法人京都大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
BR0307548A (pt) * 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo

Also Published As

Publication number Publication date
EP2089059A2 (en) 2009-08-19
WO2008063932A2 (en) 2008-05-29
US20120009185A1 (en) 2012-01-12
JP2010509369A (ja) 2010-03-25
AU2007323925A1 (en) 2008-05-29
WO2008063932A3 (en) 2008-09-04
US20100111963A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
AU2005299701B2 (en) Method for treating intraocular neovascular diseases
US20100111963A1 (en) Method for treating age-related macular degeneration
KR102724014B1 (ko) 안 질환의 치료 방법
JP2017536414A (ja) 血管性眼疾患を処置するための方法および製剤
CN104066448A (zh) 眼病的治疗
WO2007011873A2 (en) Method for treating intraocular neovascular diseases
AU2012100335A4 (en) Method for treating intraocular neovascular diseases
AU2011101626A4 (en) Method for treating intraocular neovascular diseases
AU2011101625B4 (en) Method for treating intraocular neovascular diseases
AU2011101624B4 (en) Method for treating intraocular neovascular diseases
AU2011101623A4 (en) Method for treating intraocular neovascular diseases
AU2011101627B4 (en) Method for treating intraocular neovascular diseases
AU2011101622A4 (en) Method for treating intraocular neovascular diseases
HK1102106B (en) Method for treating intraocular neovascular diseases
HK1151989A (en) Method for treating intraocular neovascular diseases
HK1151219A (en) Method for treating intraocular neovascular diseases
HK1151222A (en) Method for treating intraocular neovascular diseases
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141112